Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 11/20 | 0.41 |
| ▸ | PARP1 | P09874 | 6/20 | 0.41 |
| ▸ | PARP11 | Q9NR21 | 6/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.33 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.33 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.33 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.31 |
| ▸ | F7 | P08709 | 1/20 | 0.31 |
| ▸ | F3 | P13726 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17541302 | 0.77 | ITGAV (0.35) | PARP10PARP1 | |
| SCHEMBL14107440 | 0.73 | PARP10 (0.49) | PARP10PARP1PARP11PDPK1PARP15 | |
| SCHEMBL19553066 | 0.70 | PARP10 (0.36) | PARP10PARP1PARP11PARP15PARP14 | |
| SCHEMBL25796894 | 0.69 | PARP10 (0.51) | PARP10PARP1PARP11MAPKAPK2 | |
| SCHEMBL30549857 | 0.69 | PARP10 (0.51) | PARP10PARP1PARP11MAPKAPK2 | |
| SCHEMBL14107468 | 0.69 | PARP10 (0.55) | PARP10PARP1PARP11PDPK1PARP15 | |
| SCHEMBL30097771 | 0.68 | MKNK1 (0.40) | PARP10PARP1PARP11PDPK1MAPKAPK2 | |
| SCHEMBL26505847 | 0.68 | MKNK1 (0.40) | PARP10PARP1PARP11PDPK1MAPKAPK2 | |
| SCHEMBL1620576 | 0.68 | HTR2C (0.51) | — | |
| SCHEMBL3133143 | 0.67 | CYP11B2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1784188-B1 | FUSED TRIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME (US) | 2010-07-14 | — | — | EP | disclosed |
| US-7625888-B2 | Fused triazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20070208010-A1 | Fused Triazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME CORP. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208010-A1 | Fused Triazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | PARP10 2736/4885PARP1 2300/4885PARP11 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.